Individuals with obesity have been shown to have a greater glycaemic reduction on thiazolidinediones (TZD), compared with individuals without obesity, whereas a higher BMI is associated with a smaller glycaemic reduction on DPP4-inhibitors (DPP4i)8,9. The gene discussed is DPP4; the disease is obesity disorder.